Imaging pulmonary emboli and deep venous thrombi with Tc-99m-bitistatin, aplatelet-binding polypeptide from viper venom

Citation
Lc. Knight et al., Imaging pulmonary emboli and deep venous thrombi with Tc-99m-bitistatin, aplatelet-binding polypeptide from viper venom, J NUCL MED, 41(6), 2000, pp. 1056-1064
Citations number
36
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Journal title
JOURNAL OF NUCLEAR MEDICINE
ISSN journal
01615505 → ACNP
Volume
41
Issue
6
Year of publication
2000
Pages
1056 - 1064
Database
ISI
SICI code
0161-5505(200006)41:6<1056:IPEADV>2.0.ZU;2-0
Abstract
An imaging test that could locate both pulmonary emboli (PE) and their sour ce, active deep venous thrombi (DVT), would be valuable in patient manageme nt. Bitistatin, an 83-amino-acid polypeptide isolated from Bitis arietans v enom, binds avidly to the glycoprotein IIb/IIIa receptor on platelets. The goal of this study was to label bitistatin with Tc-99m and assess its poten tial for imaging thrombi and emboli in vivo. Methods: Molecular modeling of bitistatin indicated that its primary amines are located on the opposite s ide of the molecule from the receptor-binding domain. The primary amines we re reacted with succinimidyl-4-hydrazino nicotinate hydrochloride to place 2.4 hydrazino nicotinate (Mn) chelating groups per peptide molecule. Hn-bit istatin was labeled by incubation with Tc-99m-glucoheptonate to 96 TBq/mmol and then tested for binding to platelets in vitro and for imaging of 24-h- old DVT and PE in a canine model used previously for other thrombus tracers . Results: Tc-99m-Hn-bitistatin bound to stimulated platelets with a dissoc iation constant (K-d) = 32 nmol/L, similar to that of I-125-bitistatin (K-d = 41 nmol/L). In vivo, focal uptake was observed in planar images as early as 30 min (DVT) and 60 min (PE) after injection. Lesion uptake of Tc-99m-H n-bitistatin at 4 h after injection was calculated in terms of percentage i njected dose per gram (%ID/g) of tissue and averaged 0.89 %ID/g PE and 0.79 %ID/g DVT. Lesion-to-background ratios averaged 34:1 (PE-to-lung), 18:1 (D VT-to-blood), and 284:1 (DVT-to-muscle). These values were not significantl y different from iodinated bitistatin, but uptakes were higher than other t racers tested in the same model. Conclusion: Tc-99m-Hn-bitistatin retains t he functional activity of the iodinated peptide, has higher DVT and PE upta kes than other thrombus tracers in this standardized model, and has target- to-background characteristics suitable for imaging both PE and DVT in a sin gle test.